Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losmapimod extension study in adults with FSHD1
NL-OMON59568Phase 2Completed
- Sponsor
- Fulcrum Therapeutics
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD), sponsored by Fulcrum Therapeutics. Primary endpoint: Safety and tolerability. Started Aug 2019; status: completed.
02
Drugs
losmapimod
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NL-OMON59568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59568.